Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2015181380 |
Title |
Cyclopropylamine Compounds As Histone Demethylase Inhibitors. |
Abstract |
The present disclosure relates to cyclopropyl compounds of general formula (I), wherein R1, and R2 are as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy. |
Applicant(s) |
Ieo - Istituto Europeo Di Oncologia Srl |
Representative Drug(s) |
D06XEU |
Drug Info
|
IC50 < 1000 nM |
Click to Show More |
[1] |
2
|
D0L4OH
|
Drug Info
|
IC50 < 1000 nM
|
[1] |
Patent ID |
WO2015156417 |
Title |
Cyclopropanamine Compound and Use Thereof. |
Abstract |
The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof. |
Applicant(s) |
Takeda Pharmaceutical Company Limited |
Representative Drug(s) |
D07DIJ |
Drug Info
|
IC50 < 100 nM |
Click to Show More |
[1] |
2
|
D02CIX
|
Drug Info
|
IC50 = 180 nM
|
[1] |
3
|
D0R2YA
|
Drug Info
|
IC50 = 210 nM
|
[1] |
4
|
D04PWX
|
Drug Info
|
IC50 = 230 nM
|
[1] |
5
|
D0W9VF
|
Drug Info
|
IC50 = 240 nM
|
[1] |
Patent ID |
WO2015120281 |
Title |
Aminotriazole- and Aminotetrazole-Based Kdm1A Inhibitors As Epigenetic Modulators. |
Abstract |
In some aspects, the present invention provides compounds of the formula (IV), wherein the variables are as defined herein, which may be used as inhibitors of histone demethylase or spermine oxidase. Also provided herein are pharmaceutical compositions of the compounds and methods using the compounds in the treatment of diseases such as cancer and cardiovascular disease. |
Applicant(s) |
Musc Foundation for Research Development |
Representative Drug(s) |
D0W8XM |
Drug Info
|
IC50 = 1190 nM |
Click to Show More |
[1] |
2
|
D02YGX
|
Drug Info
|
IC50 = 2220 nM
|
[1] |
Patent ID |
WO2014205213 |
Title |
Substituted (E)-N'-(1-Phenylethylidene) Benzohydrazide Analogs As Histone Demethylase Inhibitors. |
Abstract |
Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs or (3-(5-chloro-2-hydroxyphenyl)-4-METHYL-1 H-pyrazol-1-YL)(3- (morpholinosulfonyl)phenyl)methanone, derivatives thereof, and related compounds are useful as inhibitors of lysine-specific histone demethylase, including LSD1. Synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1 (lysine-specific demethylase). A pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof, and one or more of: (a) at least one agent known to increase histone demethylase activity; (b) at least one agent known to decrease histone demethylase activity; (c) at least one agent known to treat a disorder of uncontrolled cellular proliferation; (d) at least one agent known to treat a neurodegenerative disorder; (e) instructions for treating a neurodegenerative disorder; or (f) instructions for treating a disorder associated with uncontrolled cellular proliferation. |
Applicant(s) |
University of Utah Research Foundation |
Representative Drug(s) |
D0WT1Z |
Drug Info
|
IC50 = 13 nM |
Click to Show More |
[1] |
2
|
D05FVW
|
Drug Info
|
IC50 = 19 nM
|
[1] |
3
|
D0GA7D
|
Drug Info
|
IC50 > 3000 nM
|
[1] |
4
|
D0UG5Q
|
Drug Info
|
IC50 > 3000 nM
|
[1] |
Patent ID |
WO2014194280 |
Title |
Novel Suicidal Lsd1 Inhibitors Targeting Sox2-Expressing Cancer Cells. |
Abstract |
Disclosed are inhibitors of lysine-specific demethylase I (LSD1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating cancers characterized by the presence of Sox2 using the compounds and compositions Also disclosed are methods of treating cancers characterized by the presence of Sox2 using inhibitors of LSD 1 and/or histone deacetylation I (HDAC1). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. |
Applicant(s) |
The Board of Regents of the Nevada System of Higher Education On Behalf of the University of Nevada, Las Vegas |
Representative Drug(s) |
D08FVR |
Drug Info
|
IC50 = 31380 nM |
Click to Show More |
[1] |
2
|
D0I9QC
|
Drug Info
|
IC50 = 39380 nM
|
[1] |
Patent ID |
WO2013025805 |
Title |
Substituted (E)-N'-(1-Phenylethylidene) Benzohydrazide Analogs As Histone Demethylase Inhiitors. |
Abstract |
In one aspect, the invention relates to substituted (E)-N'-(1- phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. |
Applicant(s) |
University of Utah Research Foundation |
Representative Drug(s) |
D0WT1Z |
Drug Info
|
IC50 = 13 nM |
Click to Show More |
[1] |
2
|
D05FVW
|
Drug Info
|
IC50 = 19 nM
|
[1] |
Patent ID |
WO2012071469 |
Title |
Histone Demethylase Inhibitors and Uses Thereof for Treatment O F Cancer. |
Abstract |
A compound of formula I: or a pharmaceutically acceptable salt, Ri is an optionally substituted heterocyclic group; R and R' are independently H, CH3, NO2, SO2N(CH3)2, SO2N((CH3)SO2), COOH, COOCH3, CO(N(CH3)), alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heteroaryl, heterocycloalkyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, trifluoromethyl, pentafluoroethyl, halogen, cyano, thio, amido, ether, ester, hydroxyl, hydroxyalkyl, saturated or unsaturated fatty acids, azido, phosphonamido, sulfonamido, lactam, phosphate, phosphonato, phosphinato, amino, acylamino, amidino, imino, guanidino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, or azido; m and n are independently integers from 1 to 4; T, U, V, and Z are independently CH, N, or CR; L is NH, CH2, O, S, or SO2; X is N or CH; Y and Y' are independently O or S; and R3 is an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group. |
Applicant(s) |
Nevada Cancer Institute |
Representative Drug(s) |
D0DD4I |
Drug Info
|
IC50 = 5270 nM |
Click to Show More |
[1] |
2
|
D0YX4R
|
Drug Info
|
IC50 = 10540 nM
|
[1] |
3
|
D0VB7F
|
Drug Info
|
IC50 = 11160 nM
|
[1] |
Patent ID |
WO2012042042 |
Title |
Selective Lsd1 and Dual Lsd1/Mao-B Inhibitors for Modulating Diseases Associated with Alterations In Protein Conformation. |
Abstract |
The invention relates to methods and compositions for the treatment or prevention of protein conformation disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing a protein conformation disorder, such as, e.g., Huntington Disease. |
Applicant(s) |
Oryzon Genomics, Sa |
Representative Drug(s) |
D0IO2A |
Drug Info
|
IC50 < 20 nM |
Click to Show More |
[2] |
2
|
D06KBT
|
Drug Info
|
IC50 < 30 nM
|
[2] |
3
|
D0Q1EG
|
Drug Info
|
IC50 < 50 nM
|
[2] |
4
|
D01CIK
|
Drug Info
|
IC50 = 100 nM
|
[2] |
5
|
D06VMN
|
Drug Info
|
IC50 = 100 nM
|
[2] |
6
|
D0AI6J
|
Drug Info
|
IC50 < 100 nM
|
[2] |
7
|
D0PM2S
|
Drug Info
|
IC50 < 100 nM
|
[2] |
8
|
D02WXS
|
Drug Info
|
IC50 < 200 nM
|
[2] |
9
|
D0E7SF
|
Drug Info
|
IC50 < 200 nM
|
[2] |
Patent ID |
WO2012013728 |
Title |
Arylcyclopropylamine Based Demethylase Inhibitors of Lsd1 and Their Medical Use. |
Abstract |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). |
Applicant(s) |
Oryzon Genomics Sa |
Patent ID |
WO2011131697 |
Title |
Lysine Specific Demethylase-1 Inhibitors and Their Use. |
Abstract |
The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each ('), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (') is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, -CH2C(=0)NH2, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is -NH-; (L) is chosen from a single bond, -CH2-, -CH2CH2-, -CH2CH2CH2-, and -CH2CH2CH2CH2-; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from - NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. (A')X-(A)-(B)-(Z)-(L)-(D) formula (I) The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer. |
Applicant(s) |
Oryzon Genomics Sa |
Representative Drug(s) |
D07NTA |
Drug Info
|
EC50 = 8 nM |
Click to Show More |
[1] |
2
|
D01CIK
|
Drug Info
|
IC50 = 100 nM
|
[1] |
3
|
D06VMN
|
Drug Info
|
IC50 = 100 nM
|
[1] |
4
|
D0LK8A
|
Drug Info
|
IC50 = 100 to 1000 nM
|
[1] |
Patent ID |
WO2011131576 |
Title |
Tranylcypromine Derivatives As Inhibitors of Histone Demethylase Lsd1 and/or Lsd2. |
Abstract |
Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e.g. tumors, viral infections, are herein described. These compounds belong to the structural formula (I) wherein A and R3 are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof. |
Applicant(s) |
Univ Roma |
Representative Drug(s) |
D04OHC |
Drug Info
|
IC50 = 1100 to 1900 nM |
Click to Show More |
[1] |
2
|
D0BG7B
|
Drug Info
|
Ki = 1300 nM
|
[1] |
3
|
D0O7IH
|
Drug Info
|
IC50 = 1300 to 40000 nM
|
[1] |
Patent ID |
WO2011106573 |
Title |
Lysine Demethylase Inhibitors for Diseases and Disorders Associated with Hepadnaviridae. |
Abstract |
The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal. |
Applicant(s) |
Oryzon Genomics, Sa |
Representative Drug(s) |
D07MQD |
Drug Info
|
IC50 = 1 to 100 nM |
Click to Show More |
[1] |
2
|
D0UE4K
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
3
|
D0YI0V
|
Drug Info
|
IC50 = 100 nM
|
[1] |
Patent ID |
WO2011035941 |
Title |
Lysine Specific Demethylase-1 Inhibitors and Their Use. |
Abstract |
The invention relates to a compound of Formula (I): (A')x-(A)-(B)-(Z)-(L)-(D), wherein: (A) is heteroaryl or aryl; each (A'), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A') is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, aryl, arylalkoxy, alkyl, alkoxy, cyano, sulfonyl, amido, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is -NH-; (L) is chosen from -CH2CH2-, -CH2CH2CH2-, and -CH2CH2CH2CH2-; and (D) is chosen from -N(-R1)-R2, -O-R3, and -S-R3, wherein: R1 and R2 are mutually linked to form a heterocyclic ring together with the nitrogen atom that R1 and R2 are attached to, wherein said heterocyclic ring has 0, 1, 2, or 3 substituents independently chosen from -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, cyano, alkoxy, haloalkyl, and haloalkoxy, or R1 and R2 are independently chosen from -H, alkyl, cycloalkyl, haloalkyl, and heterocyclyl, wherein the sum of substituents on R1 and R2 together is 0, 1, 2, or 3, and the substituents are independently chosen from -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), and fluoro; and R3 is chosen from -H, alkyl, cycloalkyl, haloalkyl, and heterocyclyl, wherein R3 has 0, 1, 2, or 3 substituents independently chosen from -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), and fluoro; or an enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof. The compounds of the invention show inhibitory LSD1 activity, which makes them useful in the treatment or prevention of diseases such as cancer. |
Applicant(s) |
Oryzon Genomics Sa |
Representative Drug(s) |
D03MPD |
Drug Info
|
IC50 = 1 to 100 nM |
Click to Show More |
[1] |
2
|
D0O2WW
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
Patent ID |
WO2010043721 |
Title |
Oxidase Inhibitors and Their Use. |
Abstract |
The invention relates to phenylcyclopropylamine acetamide derivatives and their use in treating diseases. |
Applicant(s) |
Oryzon Genomics Sa |
Representative Drug(s) |
D0XH9M |
Drug Info
|
IC50 = 18 nM |
Click to Show More |
[1] |
2
|
D08IOP
|
Drug Info
|
IC50 = 22 nM
|
[1] |
3
|
D0UL9U
|
Drug Info
|
Ki < 1000 nM
|
[1] |
Patent ID |
WO2015031564 |
Title |
Substituted-1H-Benzo[D]Imidazole Compounds As Lysine-Specific Demethylase 1 (Lsd1 ) Inhibitors. |
Abstract |
The present invention provides compounds which are useful as inhibitors of lysine-specific demethylase 1 (LSD1 ) and pharmaceutical compositions comprising the same. The present invention also relates to a method for decreasing histone demethylase activity and treating a mammalian disorder in which LSD1 levels are elevated by administering these compounds and compositions to a patient in need thereof. |
Applicant(s) |
University of Utah |
Representative Drug(s) |
D0WT1Z |
Drug Info
|
IC50 = 13 nM |
Click to Show More |
[1] |
2
|
D05FVW
|
Drug Info
|
IC50 = 19 nM
|
[1] |
3
|
D0J1HQ
|
Drug Info
|
IC50 = 81 nM
|
[1] |
4
|
D0RC0G
|
Drug Info
|
IC50 = 90 nM
|
[1] |
5
|
D0MO5Y
|
Drug Info
|
IC50 = 273 nM
|
[1] |
Patent ID |
WO2015089192 |
Title |
Inhibitors of Lysine Specific Demethylase-1. |
Abstract |
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. |
Applicant(s) |
Celgene Quanticel Research, Inc |
Representative Drug(s) |
D07LKA |
Drug Info
|
IC50 < 100 nM |
Click to Show More |
[1] |
2
|
D0L0DT
|
Drug Info
|
N.A.
|
[1] |
3
|
D0N2QZ
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2014084298 |
Title |
Lsd1-Selective Inhibitor Having Lysine Structure. |
Abstract |
The present invention mainly addresses the problem of providing a novel compound having a LSD1-selective inhibitory activity and also having an antitumor/anti-cancer activity, an anti-virus activity. |
Applicant(s) |
Kyoto Prefectural Public University Corporation |
Representative Drug(s) |
D0BE4Z |
Drug Info
|
IC50 = 10 to 1000 nM |
Click to Show More |
[1] |
2
|
D0D9CK
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2012135113 |
Title |
Cyclopropylamines As Lsd1 Inhibitors. |
Abstract |
This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1(LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer. |
Applicant(s) |
Glaxosmithkline Intellectual Property (No.2) Limited |
Representative Drug(s) |
D0C0PK |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0F1CT
|
Drug Info
|
N.A.
|
[1] |
3
|
D0KZ5T
|
Drug Info
|
N.A.
|
[1] |
4
|
D0LR6D
|
Drug Info
|
N.A.
|
[1] |
5
|
D0NJ6B
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2014085613 |
Title |
Hydroxytyrosol and Oleuropein Compositions for Induction of Dna Damage, Cell Death and Lsd1 Inhibition. |
Abstract |
Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided. |
Applicant(s) |
Mccord, Darlene E. et al |
Representative Drug(s) |
D0DL5J |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0P4NF
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2013033688 |
Title |
Treatment of Cancer. |
Abstract |
This disclosure provides agents, compositions and methods of treating cancer by inhibiting histone lysine specific demethylase 1 ( LSD1) and/or and a histone lysine specific demethylase 2 (LSD2). Agents and compositions comprise statins and/or inhibitors of LSD1/2. |
Applicant(s) |
The Brigham and Women'S Hospital, Inc |
Representative Drug(s) |
D09OMM |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0WO5W
|
Drug Info
|
N.A.
|
[1] |
3
|
D0Z7HE
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2012034116 |
Title |
Small Molecules As Epigenetic Modulators of Lysine-Specific Demethylase 1 and Methods of Treating Disorders. |
Abstract |
The invention provides for novel compounds which are inhibitors of lysine- specific demethylase 1 (LSDl). Such compounds may be used to treat disorders, including cancer. |
Applicant(s) |
The Johns Hopkins University |
Representative Drug(s) |
D05HBM |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D08WMK
|
Drug Info
|
N.A.
|
[1] |
3
|
D0KR0I
|
Drug Info
|
N.A.
|
[1] |
4
|
D0U1DY
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2015134973 |
Title |
Inhibitors of Histone Lysine Specific Demethylase (Lsd1) and Histone Deacetylases (Hdacs). |
Abstract |
A series of phenelzine analogs comprising a phenelzine scaffold linked to an aromatic moiety and their use as inhibitors of lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) is provided. The presently disclosed phenelzine analogs exhibit potency and selectivity for LSD1 versus MAO and LSD2 enzymes and exhibit bulk, as well as, gene specific histone methylation changes, anti-proliferative activity in several cancer cell lines, and neuroprotection in response to oxidative stress. Accordingly, the presently disclosed phenelzine analogs can be used to treat diseases, conditions, or disorders related to LSD1 and/or HDACs, including, but not limited to, cancers and neurodegenerative diseases. |
Applicant(s) |
The Johns Hopkins University |
Representative Drug(s) |
D0U4DT |
Drug Info
|
IC50 = 59 nM |
[1] |
Patent ID |
WO2014164867 |
Title |
Kdm1A Inhibitors for The Treatment of Disease. |
Abstract |
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, and methods of increasing gamma globin gene expression in a human or animal subject are also provided for the treatment diseases such as sickle cell disease. |
Applicant(s) |
Imago Biosciences |
Representative Drug(s) |
D0BE4Z |
Drug Info
|
IC50 = 10 to 1000 nM |
[1] |
Patent ID |
WO2013057322 |
Title |
(Hetero)Aryl Cyclopropylamine Compounds As Lsd1 Inhibitors. |
Abstract |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. |
Applicant(s) |
Oryzon Genomics, Sa |
Representative Drug(s) |
D07NTA |
Drug Info
|
EC50 = 8 nM |
[1] |
Patent ID |
WO2013057320 |
Title |
(Hetero)Aryl Cyclopropylamine Compounds As Lsd1 Inhibitors. |
Abstract |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. |
Applicant(s) |
Oryzon Genomics, Sa |
Representative Drug(s) |
D07NTA |
Drug Info
|
EC50 = 8 nM |
[1] |
Patent ID |
WO2012072713 |
Title |
Lysine Demethylase Inhibitors Such As Cyclylcyclopropanamine Derivatives for Use In The Treatment of Diseases and Disorders Associated with Flaviviridae. |
Abstract |
The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor such as 2 - cyclyldyclopropan - 1 - amine derivatives, phenelzine derivatives and propargylamine derivatives for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections. |
Applicant(s) |
Oryzon Genomics, Sa |
Representative Drug(s) |
D0YI0V |
Drug Info
|
IC50 = 100 nM |
[1] |
Patent ID |
WO2012045883 |
Title |
Cyclopropylamine Inhibitors of Oxidases. |
Abstract |
The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer. |
Applicant(s) |
Oryzon Genomics Sa |
Representative Drug(s) |
D0B6GK |
Drug Info
|
IC50 = 1 to 100 nM |
[1] |
Patent ID |
WO2012013727 |
Title |
Cyclopropylamine Derivatives Useful As Lsd1 Inhibitors. |
Abstract |
The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection. |
Applicant(s) |
Oryzon Genomics S.A |
Representative Drug(s) |
D0B6GK |
Drug Info
|
IC50 = 1 to 100 nM |
[1] |
Patent ID |
WO2014205511 |
Title |
Methods and Compositions for Modulating Cancer Stem Cells. |
Abstract |
Disclosed are compositions and methods that use lysine demethylase inhibitors for inhibiting the growth of cancer stem cells or tumor initiating cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer5 cells and/or for preventing cancer recurrence. |
Applicant(s) |
University of Canberra |
Representative Drug(s) |
D0D9CK |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2012156537 |
Title |
Lysine Demethylase Inhibitors Such As Cyclylcylopropamine Derivatives for Use In The Treatment of Thrombosis and Cardiovascular Diseases. |
Abstract |
The invention relates to methods and compositions for the treatment or prevention of thrombosis, thrombus formation, a thrombotic event or complication, or a cardiovascular disease or event. In particular, the invention relates to an LSD inhibitor such as a 2-cyclylcyclopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use in treating or preventing thrombosis, thrombus formation, a thrombotic event or complication, or a cardiovascular disease or event. |
Applicant(s) |
Oryzon Genomics, Sa |
Patent ID |
WO2012156531 |
Title |
Lysine Demethylase Inhibitors Such As Cyclylcylopropamine Derivatives for Use In The Treatment of Inflammatory Diseases or Conditions. |
Abstract |
The invention relates to methods and compositions for the treatment or prevention of inflammation and inflammatory diseases or conditions. In particular, the invention relates to an LSD1 inhibitor, such as a 2-cyclylcylopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use in treating or preventing inflammation and inflammatory diseases or conditions. |
Applicant(s) |
Oryzon Genomics Sa |
Patent ID |
WO2011106106 |
Title |
Lysine Demethylase Inhibitors for Diseases and Disorders Associated with Hepadnaviridae. |
Abstract |
The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal. |
Applicant(s) |
Oryzon Genomics, Sa |
Patent ID |
WO2011106105 |
Title |
Inhibitors for Antiviral Use. |
Abstract |
The present invention relates to the use of potent selective LSD1 inhibitors and LSD1/MAO-B inhibitors for treating or preventing viral infections. Furthermore, the present invention relates to the new use of cyclopropylamine acetamide derivatives or cyclopropylamine derivatives, as defined herein, for treating or preventing viral infection and treating or preventing reactivation of a virus after latency. |
Applicant(s) |
Oryzon Genomics, Sa |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US20140343118 |
Title |
Preparation of Arylcyclopropylamine Compounds Useful for The Treatment of Breast Cancer. |
Applicant(s) |
Duke University, USA |
Representative Drug(s) |
D0JE6I |
Drug Info
|
Ki = 173000 nM |
Click to Show More |
[1] |
2
|
D07IAO
|
Drug Info
|
Ki = 352000 nM
|
[1] |
3
|
D0C1TH
|
Drug Info
|
Ki = 456000 nM
|
[1] |
Patent ID |
US20140163017 |
Title |
Preparation of Substituted (E)-N-(1-Phenylethylidene)Benzohydrazide Analogs As Histone Demethylase Inhibitors Patent. |
Applicant(s) |
University of Utah, Usa |
Representative Drug(s) |
D0WT1Z |
Drug Info
|
IC50 = 13 nM |
Click to Show More |
[1] |
2
|
D05FVW
|
Drug Info
|
IC50 = 19 nM
|
[1] |
3
|
D0GA7D
|
Drug Info
|
IC50 > 3000 nM
|
[1] |
4
|
D0UG5Q
|
Drug Info
|
IC50 > 3000 nM
|
[1] |
Patent ID |
US20150225401 |
Title |
Cyclopropylamines As Lsd1 Inhibitors and Their Preparation. |
Applicant(s) |
Incyte Corporation, USA |
Representative Drug(s) |
D0R7RY |
Drug Info
|
IC50 = 100 to 500 nM |
[1] |
Patent ID |
US20150225394 |
Title |
Cyclopropylamines As Lsd1 Inhibitors and Their Preparation. |
Applicant(s) |
Incyte Corporation, USA |
Representative Drug(s) |
D0R7RY |
Drug Info
|
IC50 = 100 to 500 nM |
[1] |
Patent ID |
US20150225379 |
Title |
Cyclopropylamines As Lsd1 Inhibitors and Their Preparation. |
Applicant(s) |
Incyte Corporation, USA |
Representative Drug(s) |
D0R7RY |
Drug Info
|
IC50 = 100 to 500 nM |
[1] |
Patent ID |
US20150225375 |
Title |
Cyclopropylamines As Lsd1 Inhibitors and Their Preparation. |
Applicant(s) |
Incyte Corporation, USA |
Representative Drug(s) |
D0R7RY |
Drug Info
|
IC50 = 100 to 500 nM |
[1] |
Patent ID |
US20150065434 |
Title |
Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1. |
Applicant(s) |
Musc Foundation for Research Development |
Representative Drug(s) |
D04OEV |
Drug Info
|
IC50 = 5000 nM |
[1] |
Patent ID |
US20100324147 |
Title |
Trans-2-Arylcyclopropylamine Derivatives As Inhibitors of Lysine-Specific Demethylase 1, Monoamine Oxidase A and B, and Their Preparation and Use for The Treatment of Cancer. |
Applicant(s) |
Duke University, Usa |
European Patent Office (EPO) |
Patent ID |
EP2177502 |
Title |
Preparation of N-(2 Phenylcyclopropyl) Amino Acid Derivatives for Treatment of Cancer. |
Applicant(s) |
Oryzon Genomics Sa, Spain |
Representative Drug(s) |
D0XH9M |
Drug Info
|
IC50 = 18 nM |
Click to Show More |
[1] |
2
|
D08IOP
|
Drug Info
|
IC50 = 22 nM
|
[1] |
3
|
D0UL9U
|
Drug Info
|
Ki < 1000 nM
|
[1] |